The APOBEC3A Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the human lung adenocarcinoma cell line A-549, bearing a disruption of the APOBEC3A gene. This loss-of-function model is generated via CRISPR/Cas9-mediated gene targeting, resulting in a heterogeneous pool of cells with targeted edits, avoiding clonal selection artifacts. The polyclonal format preserves cellular diversity while enabling robust loss-of-function studies of APOBEC3A in a relevant cancer context. The product is supplied as a validated polyclonal knockout population, suitable for downstream functional and phenotypic analyses without the need for single-cell cloning.
The host A-549 cell line is a well-characterized human lung carcinoma model exhibiting adherent epithelial morphology and derived from the tumor tissue of a 58-year-old Caucasian male. These cells retain features of alveolar type II pneumocytes and are widely utilized to investigate lung adenocarcinoma biology, including oncogenic signaling, tumor microenvironment interactions, and therapeutic responses. The A-549 background provides a clinically relevant platform for studying APOBEC3A function, as lung adenocarcinoma is among the cancers in which APOBEC-mediated mutagenesis is frequently observed.
APOBEC3A is a cytidine deaminase that catalyzes C>U editing on single-stranded DNA substrates, including viral genomes and retrotransposons, thereby restricting HIV-1 and HBV replication and generating clustered somatic hypermutations (kataegis). Its expression is activated by IFN-?? and IFN-?? through the IFNAR1/2 receptor and the STAT1/STAT2/IRF9 (ISGF3) complex, as well as by TNF-??. Within cells, APOBEC3A interacts with DNA replication and repair proteins such as RPA, PCNA, and UNG2, coupling deamination to downstream DNA damage responses. Knockout of APOBEC3A abolishes this enzymatic activity, preventing the associated mutagenesis and enabling clean dissection of its contributions to innate immunity and genome instability.
Use of the A-549 lung adenocarcinoma background is particularly relevant because APOBEC3A mutagenesis is frequently observed in lung cancer genomes. Disruption of APOBEC3A in this model allows researchers to differentiate its mutagenic impact from other oncogenic drivers and to explore its role in tumor evolution and therapy resistance. Additionally, since A-549 cells retain active interferon signaling, this knockout system facilitates studies of APOBEC3A regulation by innate immune pathways and its consequent effects on DNA damage and viral susceptibility in a lung epithelial context.
Key experimental applications include quantifying APOBEC-mediated mutation signatures via sequencing, measuring C-to-U editing activity, assessing interferon pathway activation through phospho-STAT1/STAT2 analysis, and testing antiviral restriction against HIV-1 or HBV. The polyclonal knockout cells are also suited for inhibitor screening and protein interaction studies (e.g., UNG2 or RPA co-immunoprecipitation). Standard techniques such as Western blotting and immunofluorescence confirm APOBEC3A loss, while DNA damage foci assays (??H2AX) assess genomic stability. For detailed protocols or support, contact Ascent Research.
